Literature DB >> 31988246

The extracellular sulfatase SULF2 promotes liver tumorigenesis by stimulating assembly of a promoter-looping GLI1-STAT3 transcriptional complex.

Ryan M Carr1, Paola A Romecin Duran1, Ezequiel J Tolosa1, Chenchao Ma2, Abdul M Oseini2, Catherine D Moser2, Bubu A Banini2, Jianbo Huang2, Faizal Asumda2, Renumathy Dhanasekaran2, Rondell P Graham3, Merih D Toruner1, Stephanie L Safgren1, Luciana L Almada1, Shaoqing Wang2, Mrinal M Patnaik4, Lewis R Roberts5, Martin E Fernandez-Zapico6.   

Abstract

The expression of the extracellular sulfatase SULF2 has been associated with increased hepatocellular carcinoma (HCC) growth and poor patient survival. However, the molecular mechanisms underlying SULF2-associated tumor growth remain unclear. To address this gap, here we developed a transgenic mouse overexpressing Sulf2 in hepatocytes under the control of the transthyretin promoter. In this model, Sulf2 overexpression potentiated diethylnitrosamine-induced HCC. Further analysis indicated that the transcription factor GLI family zinc finger 1 (GLI1) mediates Sulf2 expression during HCC development. A cross of the Sulf2-overexpressing with Gli1-knockout mice revealed that Gli1 inactivation impairs SULF2-induced HCC. Transcriptomic analysis revealed that Sulf2 overexpression is associated with signal transducer and activator of transcription 3 (STAT3)-specific gene signatures. Interestingly, the Gli1 knockout abrogated SULF2-mediated induction of several STAT3 target genes, including suppressor of cytokine signaling 2/3 (Socs2/3); Pim-1 proto-oncogene, Ser/Thr kinase (Pim1); and Fms-related tyrosine kinase 4 (Flt4). Human orthologs were similarly regulated by SULF2, dependent on intact GLI1 and STAT3 functions in HCC cells. SULF2 overexpression promoted a GLI1-STAT3 interaction and increased GLI1 and STAT3 enrichment at the promoters of their target genes. Interestingly, the SULF2 overexpression resulted in GLI1 enrichment at select STAT3 consensus sites, and vice versa. siRNA-mediated STAT3 or GLI1 knockdown reduced promoter binding of GLI1 and STAT3, respectively. Finally, chromatin-capture PCR confirmed long-range co-regulation of SOCS2 and FLT3 through changes in promoter conformation. These findings define a mechanism whereby SULF2 drives HCC by stimulating formation of a GLI1-STAT3 transcriptional complex.
© 2020 Carr et al.

Entities:  

Keywords:  GLI1; STAT transcription factor; STAT3; SULF2; carcinogenesis; gene regulation; gene transcription; hepatocellular carcinoma; promoter conformation; tumorigenesis

Mesh:

Substances:

Year:  2020        PMID: 31988246      PMCID: PMC7049957          DOI: 10.1074/jbc.RA119.011146

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Quantitative analysis of chromosome conformation capture assays (3C-qPCR).

Authors:  Hélène Hagège; Petra Klous; Caroline Braem; Erik Splinter; Job Dekker; Guy Cathala; Wouter de Laat; Thierry Forné
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 2.  Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.

Authors:  Floriane Pez; Anaïs Lopez; Miran Kim; Jack R Wands; Claude Caron de Fromentel; Philippe Merle
Journal:  J Hepatol       Date:  2013-07-05       Impact factor: 25.083

3.  Endoplasmic Reticulum Stress and Chemokine Production in Cystic Fibrosis Airway Cells: Regulation by STAT3 Modulation.

Authors:  Anthony C Tang; Aabida Saferali; Gengming He; Andrew J Sandford; Lisa J Strug; Stuart E Turvey
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

4.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Tim Meyer; Ann-Lii Cheng; Anthony B El-Khoueiry; Lorenza Rimassa; Baek-Yeol Ryoo; Irfan Cicin; Philippe Merle; YenHsun Chen; Joong-Won Park; Jean-Frederic Blanc; Luigi Bolondi; Heinz-Josef Klümpen; Stephen L Chan; Vittorina Zagonel; Tiziana Pressiani; Min-Hee Ryu; Alan P Venook; Colin Hessel; Anne E Borgman-Hagey; Gisela Schwab; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

5.  Prostacyclin receptor-dependent inhibition of human erythroleukemia cell differentiation is STAT3-dependent.

Authors:  Alaster H Y Lau; Henry K H Lai; Barry H S Yeung; Sze Lee Leung; Suk Ying Tsang; Yung H Wong; Helen Wise
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-02-13       Impact factor: 4.006

6.  The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling.

Authors:  Xin Zheng; Xiaohong Gai; Shaoshan Han; Catherine D Moser; Chunling Hu; Abdirashid M Shire; Robert A Floyd; Lewis R Roberts
Journal:  Genes Chromosomes Cancer       Date:  2012-10-29       Impact factor: 5.006

7.  Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Authors:  Jean-Charles Nault; Gabrielle Couchy; Charles Balabaud; Guillaume Morcrette; Stefano Caruso; Jean-Frederic Blanc; Yannick Bacq; Julien Calderaro; Valérie Paradis; Jeanne Ramos; Jean-Yves Scoazec; Viviane Gnemmi; Nathalie Sturm; Catherine Guettier; Monique Fabre; Eric Savier; Laurence Chiche; Philippe Labrune; Janick Selves; Dominique Wendum; Camilla Pilati; Alexis Laurent; Anne De Muret; Brigitte Le Bail; Sandra Rebouissou; Sandrine Imbeaud; Paulette Bioulac-Sage; Eric Letouzé; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2016-12-07       Impact factor: 22.682

8.  Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.

Authors:  Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Tao Han; Catherine D Moser; Kenard K Jackson; Ruben Bonilla Guerrero; Ileana Aderca; Hajime Isomoto; Megan M Garrity-Park; Hongzhi Zou; Abdirashid M Shire; David M Nagorney; Schuyler O Sanderson; Alex A Adjei; Ju-Seog Lee; Snorri S Thorgeirsson; Lewis R Roberts
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

9.  PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.

Authors:  L Brault; T Menter; E C Obermann; S Knapp; S Thommen; J Schwaller; A Tzankov
Journal:  Br J Cancer       Date:  2012-06-21       Impact factor: 7.640

10.  SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.

Authors:  A Scuto; M Kirschbaum; R Buettner; M Kujawski; J M Cermak; P Atadja; R Jove
Journal:  Cell Death Dis       Date:  2013-05-16       Impact factor: 8.469

View more
  4 in total

1.  The transcription factor GLI1 cooperates with the chromatin remodeler SMARCA2 to regulate chromatin accessibility at distal DNA regulatory elements.

Authors:  Stephanie L Safgren; Rachel L O Olson; Anne M Vrabel; Luciana L Almada; David L Marks; Nelmary Hernandez-Alvarado; Alexandre Gaspar-Maia; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

2.  Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis.

Authors:  Xin Luo; Nellie A Campbell; Li He; Daniel R O'Brien; Mark S Singer; Hassan Lemjabbar-Alaoui; Keun Soo Ahn; Rory Smoot; Michael S Torbenson; Steven D Rosen; Lewis R Roberts
Journal:  Hepatology       Date:  2021-05-24       Impact factor: 17.298

3.  Antineoplastic Activity of Chrysin against Human Hepatocellular Carcinoma: New Insight on GPC3/SULF2 Axis and lncRNA-AF085935 Expression.

Authors:  Iman O Sherif; Laila A Al-Mutabagani; Dina Sabry; Nehal M Elsherbiny
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

Review 4.  Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma.

Authors:  Divya Jain; Yogesh Murti; Wasi Ullah Khan; Rajib Hossain; Mohammad Nabil Hossain; Krishn Kumar Agrawal; Rana Azeem Ashraf; Muhammad Torequl Islam; Pracheta Janmeda; Yasaman Taheri; Mohammed M Alshehri; Sevgi Durna Daştan; Balakyz Yeskaliyeva; Aliya Kipchakbayeva; Javad Sharifi-Rad; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-10-31       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.